- Home
- GDV vs IRON Comparison
GDV vs IRON Comparison
Compare GDV & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDV
- IRON
- Stock Information
- Founded
- GDV 2003
- IRON 2017
- Country
- GDV United States
- IRON United States
- Employees
- GDV N/A
- IRON N/A
- Industry
- GDV Investment Managers
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- GDV Finance
- IRON Health Care
- Exchange
- GDV Nasdaq
- IRON Nasdaq
- Market Cap
- GDV 2.2B
- IRON 2.0B
- IPO Year
- GDV N/A
- IRON N/A
- Fundamental
- Price
- GDV $26.88
- IRON $60.76
- Analyst Decision
- GDV
- IRON Strong Buy
- Analyst Count
- GDV 0
- IRON 10
- Target Price
- GDV N/A
- IRON $97.80
- AVG Volume (30 Days)
- GDV 186.0K
- IRON 299.1K
- Earning Date
- GDV 01-01-0001
- IRON 08-07-2025
- Dividend Yield
- GDV 5.81%
- IRON N/A
- EPS Growth
- GDV N/A
- IRON N/A
- EPS
- GDV N/A
- IRON N/A
- Revenue
- GDV N/A
- IRON N/A
- Revenue This Year
- GDV N/A
- IRON N/A
- Revenue Next Year
- GDV N/A
- IRON N/A
- P/E Ratio
- GDV N/A
- IRON N/A
- Revenue Growth
- GDV N/A
- IRON N/A
- 52 Week Low
- GDV $18.04
- IRON $30.82
- 52 Week High
- GDV $23.00
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- GDV 61.32
- IRON 56.26
- Support Level
- GDV $26.72
- IRON $59.74
- Resistance Level
- GDV $26.96
- IRON $63.51
- Average True Range (ATR)
- GDV 0.22
- IRON 2.05
- MACD
- GDV 0.01
- IRON -0.00
- Stochastic Oscillator
- GDV 77.01
- IRON 44.17
About GDV Gabelli Dividend & Income Trust of Beneficial Interest
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food and Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.